Imatinib Induced Facial Skin Hyperpigmentation in a Case of Chronic Myelogenous Leukemia.

authors:

avatar N Valizadeh 1 , *

Assistant Professor, Section of Hematology and Medical Oncology, Department of Medicine, Urmia University of Medical Sciences, Urmia, Iran
Shiraz E-Medical Journal: Vol.12, issue 3; 162-4
published online: July 1, 2011
article type: Research Article
received: December 24, 2010
accepted: May 3, 2011

how to cite: Valizadeh N. Imatinib Induced Facial Skin Hyperpigmentation in a Case of Chronic Myelogenous Leukemia.. Shiraz E-Med J. 2011;12(3): 162-4. 

Abstract

Background:

Imatinib is a tyrosine kinase inhibitor (TKI) which targets BCR-ABL protein in patients with chronic myelogenous leukemia (CML) and c-kit in patients with gastrointestinal stromal tu-mors (GISTs). Skin hypopigmentation is reported during Imatinib therapy. We present a case of CML who developed skin hyperpigmentation in the face during treatment with Imatinib which found chloasma-like appearance.

Full Text

Full text is available in PDF